drug pipeline

when someone mentioned the other day that Stelara (ustekinumab) was neither TNF nor anti-adhesion class of biologic, I got curious about how many classes of biologic were in the pipeline for UC.

I found this article: Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases (journals.sagepub.com/doi/full/10.1177/1756283X14558193)

There seem to be 4 primary classes, and more drugs in the UC pipeline than I thought. Even more for Chrons.

UC pipeline: VIEW IMAGE

CD pipeline: VIEW IMAGE

Post Edited (DBwithUC) : 1/9/2017 6:00:01 PM (GMT-7)

Yes, true. I think a good percent of phase II, but I am sure others do not play out in early stages.

Mostly I was interested in the broad anti-TNF, anti-alpha, downstream signaling, immunomodulator, Cytokin, and Interleukin classes. I thought there was only two classes. Each new class is also an advance in understainding of causal mechanisms, and I hope that these understandings and advances in gut microbe research come together relatively quickly over the next decade.

Plus, like Stelera, some in RA pipeline will cross over to CD and UC. IF bio-similars can help control costs, and if genetic testing can pinpoint most likely drugs to work for each person, then I don't worry so much about aging with UC.

Post Edited (DBwithUC) : 1/10/2017 9:03:33 AM (GMT-7)